Zobrazeno 1 - 10 of 108 pro vyhledávání: '"I. Nadler"'
3
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies
Autor: Jordan, Berlin, Anthony W, Tolcher, Cliff, Ding, Jennifer G, Whisenant, Ivan D, Horak, Debra L, Wood, Paul I, Nadler, Ulla Holm, Hansen, Johan, Lantto, Niels Jørgen Ø, Skartved, Mikkel W, Pedersen, Amita, Patnaik
Publikováno v: Investigational new drugs. 40(3)
Sym013 contains six humanized monoclonal antibodies that bind to non-overlapping epitopes on three human epidermal growth factor receptors (HER1-3). Preclinical studies suggested Sym013 strongly suppresses growth of multiple epithelial tumors. This i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::98991229a501f5d7fe337e7b5ad9abc7
https://pubmed.ncbi.nlm.nih.gov/35113285
Zobrazit plný text záznamu
5
P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients
Autor: Gilles Tremblay, Jean-François Denis, Debra L. Wood, Nehal Lakhani, Daniel Vilarim Araujo, Timothy A. Yap, Tina Gruosso, Maureen D. O'Connor-McCourt, Ria Ghosh, Lilian Siu, Sandra Sinclair, Paul I. Nadler
Publikováno v: Poster Presentations.
Background AVID200 is a rationally designed first-in-class receptor ectodomain trap that inhibits transforming growth factor-beta (TGF-beta) isoforms -beta1 and -beta3 with pM potency. TGF-beta signaling is highly immunosuppressive in the tumor micro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b71852e497b887a9dca65e3b3002f1f7
https://doi.org/10.1136/lba2019.10
Zobrazit plný text záznamu
6
Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
Autor: Matthew Mei, Sairah Ahmed, Philippe Armand, Natalia Lapteva, Natalie S Grover, Aung Myo, Andreas Engert, Ian W. Flinn, Peter A. Riedell, Helen E. Heslop, Paul I. Nadler
Publikováno v: Blood. 138:3847-3847
Introduction CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has been transformative in B-cell lymphoid malignancies. CD30 is a validated target for classical Hodgkin Lymphoma (cHL), as demonstrated by the activity of the anti-CD30 anti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5f9d8ad93bd4af03792c470d6862055b
https://doi.org/10.1182/blood-2021-146100
Zobrazit plný text záznamu
8
Abstract A088: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors
Autor: Kyri Papadopoulos, Nehal Lakhani, Saad A. Khan, Debra L. Wood, Robert J. Lutz, Anthony W. Tolcher, Joyce O'Shaughnessy, Sandra Sinclair, Ria Ghosh, Karla Rivas, Sharon Wilks, Barbara Burtness, Paul I. Nadler, Jason M. Melear, Yvette Cole, Sree R Chandana
Publikováno v: Molecular Cancer Therapeutics. 18:A088-A088
Background: Currently, no therapies are approved specifically for EGFR-overexpressing tumors. AVID100 is a novel anti-EGFR antibody drug conjugate (ADC, DM1 payload) that was rationally designed for anti-tumor efficacy without accompanying on-target,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54e71c123c1fc0da7eefe3b8044d074a
https://doi.org/10.1158/1535-7163.targ-19-a088
Zobrazit plný text záznamu
9
Abstract CT056: A Phase Ia/IIa trial of AVID100, an anti-EGFR antibody-drug conjugate
Autor: Sreenivasa R Chandana, Kyri Papadopoulos, Nehal Lakhani, Yvette Cole, Sandra Sinclair, Anthony W. Tolcher, Debra L. Wood, Paul I. Nadler, Karla Rivas
Publikováno v: Cancer Research. 79:CT056-CT056
Background AVID100, a rationally designed anti-EGFR-DM1 conjugate, showed potent activity in preclinical models, including cancer cell lines resistant to approved anti-EGFR monoclonal antibodies. In addition, AVID100 showed increased toxicity on tumo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e2fd0eb0467870ec6f974402f2b24348
https://doi.org/10.1158/1538-7445.am2019-ct056
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje